Dare Bioscience, Inc.
Close on Oct 19, 2026
- Market cap
- $10.51M
- P/E (TTM)
- –
- Dividend yield
- –
About Dare Bioscience
Pharmaceutical Preparations, SIC 2834
Daré Bioscience, Inc. is a biopharmaceutical company that develops and commercializes health products specifically designed for women. The company targets therapeutic areas including contraception, sexual health, vaginal health, pelvic pain, fertility, and menopause. Its commercial portfolio features XACIATO, an FDA-approved prescription vaginal gel licensed to Organon for treating bacterial vaginosis, as well as DARE to PLAY Sildenafil Cream, which is compounded under Section 503B regulations for female sexual arousal disorder. Additionally, Daré offers non-prescription consumer wellness items, including Flora Sync LF5 under the DARE to RESTORE vaginal probiotic line. The company serves female patients, healthcare providers, and consumers through telehealth services, dispensing pharmacies, and commercial partners.
The company operates primarily within the United States, utilizing third-party manufacturing facilities, pharmacy distributors, and clinical trial sites across the country. Daré Bioscience maintains no internal sales, distribution, or marketing infrastructure, relying instead on strategic commercial collaborators and registered outsourcing facilities. The provided excerpt does not disclose the location of the company's corporate headquarters.
Summary of the business section of Dare Bioscience's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Dare Bioscience, Inc.
- Headquarters
- San Diego, CA
- Address
- 3655 Nobel Drive, Suite 260 92122
- Phone
- (858) 926-7655
- Employees
- 24, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- HASKELL & WHITE LLP, Irvine, California
Stock & identifiers
- Ticker
- DARE
- Exchange
- Nasdaq
- IPO date
- Apr 14, 2014
- Shares outstanding
- 15M, Aug 12, 2026
- Public float
- $21.34M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Jul 1, 2024; 1-for-12 reverse, Jul 1, 2024; 1-for-10 reverse, Jul 20, 2017; 1-for-10 reverse, Jul 20, 2017
- SEC CIK
- 1401914
- CUSIP
- 23666P200
- ISIN
- US23666P2002
- EIN
- 20-4139823
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sabrina Martucci Johnson | Chef Executive Officer, Director | 962,062 |
| MarDee Haring-Layton | Chief Accounting Officer | – |
| Jessica D. Grossman | Director | 26,066 |
| Susan L. Kelley | Director | 23,696 |
| Robin Joan Steele | Director | 293,226 |
| William H. Rastetter | Director | 100,028 |
| Gregory W. Matz | Director | 31,347 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Sabrina Martucci Johnson | $801.08K | $585.89K | $546.86K | $19 | – |
| FY2024 Sabrina Martucci Johnson | $898.38K | $754.03K | $455.77K | $31 | – |
| FY2023 Sabrina Martucci Johnson | $1.22M | $450.42K | $751.59K | $37 | – |
| FY2022 Sabrina Martucci Johnson | $1.67M | $594.24K | $777.54K | $42 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 25, 2026, we had 24 employees.”
Corporate history
Events identified from SEC filings